AstraZeneca receives positive interim results from lung cancer drug trial
30th Jun 2022 07:13
(Sharecast News) - Pharmaceutical giant AstraZeneca has received positive results from a planned interim analysis of the AEGEAN Phase III trial on its resectable non-small cell lung cancer drug.
Read moreAstraZeneca's breast cancer drug recommended for EU marketing authorisation
27th Jun 2022 07:04
(Sharecast News) - Drugmaker AstraZeneca said on Monday that Lynparza, its HER2-negative high-risk early breast cancer drug, has been recommended for marketing authorisation in the European Union after demonstrating "a statistically significant and clinically meaningful" improvement in invasive disease-free survival.
Read moreCiti reiterates 'buy' on AstraZeneca on the back of trial results for Enhertu against breast cancer
22nd Jun 2022 10:06
(Sharecast News) - Analysts at Citi reiterated their 'buy' recommendation for shares of AstraZeneca following the release of the results of the DESTINY-Breast 04 clinical trial using its Enhertu treatment against metastatic breast cancer.
Read moreAstraZeneca receives 'positive' results from Phase III trial on eplontersen
21st Jun 2022 08:13
(Sharecast News) - Drugmaker AstraZeneca has received positive high-level results from an interim analysis of its NEURO-TTRansform Phase III trial on eplontersen, the group's hereditary transthyretin-mediated amyloid polyneuropathy drug candidate.
Read moreBerenberg stays at 'buy' for AstraZeneca after trial results for Enhertu against breast cancer
6th Jun 2022 17:48
(Sharecast News) - Analysts at Berenberg reiterated their 'buy' recommendation with a 120.0p target price for shares of AstraZeneca following the release of the company's clinical trial results for its treatment against metastatic breast cancer.
Read moreAstraZeneca-Daiichi's Enhertu reports positive survival rate results
6th Jun 2022 07:47
(Sharecast News) - A treatment for breast cancer developed by AstraZeneca and Daiichi Sankyo has been shown to double the progression-free survival rates of patients compared with chemotherapy, according to trial data released on the weekend at a conference.
Read moreAstraZeneca autoimmune treatment meets trial endpoint
5th May 2022 08:42
(Sharecast News) - AstraZeneca said its treatment for an autoimmune disease that attacks the central nervous system had met a primary endpoint in a phase 3 trial.
Read moreAstraZeneca's Imfinzi granted priority review in the US
4th May 2022 07:42
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that a supplemental biologics license application for its Imfinzi asset, in combination with standard-of-care chemotherapy, had been accepted and granted priority review in the US for patients with locally advanced or metastatic biliary tract cancer.
Read moreAstraZeneca reiterates guidance after first quarter growth
29th Apr 2022 08:23
(Sharecast News) - AstraZeneca said on Friday that its total revenue for the first quarter surged 60% to $11.39bn (£9.07bn), with growth across the company seeing it reiterate its full-year guidance.
Read moreAstrazeneca's Ultomiris receives FDA approval
28th Apr 2022 09:16
(Sharecast News) - Drugmaker AstraZeneca's Ultomiris asset has been approved in the US for adults with generalised myasthenia gravis.
Read moreAstraZeneca's Enhertu granted FDA breakthrough therapy designation
27th Apr 2022 08:34
(Sharecast News) - Drugmaker AstraZeneca's Enhertu candidate has been granted breakthrough therapy designation in the US for adult patients with HER2-low metastatic breast cancer.
Read moreFDA accepts priority review application for AstraZeneca's tremelimumab
25th Apr 2022 07:28
(Sharecast News) - Drugmaker AstraZeneca said on Monday that an application for priority review of its tremelimumab asset had been accepted by the US Food and Drug Administration.
Read moreAstraZeneca's Enhertu to be reviewed by FDA following DESTINY-Lung01 trial
19th Apr 2022 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Enhertu candidate had been granted priority review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.
Read moreBerenberg raises target price on AstraZeneca
12th Apr 2022 10:18
(Sharecast News) - Analysts at Berenberg raised their target price on AstraZeneca shares from £100 to £120 on Tuesday, stating the stock was now "hot to trop".
Read moreJP Morgan ups AstraZeneca target price on potential for oncology pipeline
7th Apr 2022 14:27
(Sharecast News) - Analysts at JP Morgan hiker their target price for shares of AstraZeneca and pointed to the potential for "significant" future upward revisions to analysts' estimates for the profitability of the company's oncology pipeline.
Read more